redspeed: I do appreciate the difficult job Gerald
Post# of 30081
Posted On: 12/17/2014 9:49:36 PM
redspeed: I do appreciate the difficult job Gerald is doing. He is building a strong company for the distant future. (4-6 years) I just happen to be an investor that needs to see value in the near future.
I can wait to up list until February. Personally, I hope we don't partner yet. I am hoping AMBS starts signing up pharmas doing AD trials. If we start seeing commitments from pharmas to use Lympro in January, the stock price will shoot up without the up front cash of a partner!! And then in 6 to 12 months, a partner will pay us 100x to partner with us on LymPro. (You got the quote right.)
I will be happy if the "launch" means: 1) We get the most recent Lympro data, and 2) We get 2 or 3 pharmas committed to Lympro by the end of January. If that happens, everything else will take care of itself....trust me.
All the surges we've had in stock price have always been associated with enthusiasm over Lympro. Jason Napodana took a dump on LymPro with his 1 million revenue estimate for 2015. That put a wet blanket over the stock price. If during the "launch" Gerald dispels that estimate and gives us better guidance aligned with his previous "significant portion of the 150 million RUO market in 2015," the stock price will start moving up.
If by the end of January we have 3 pharma commitments to use LymPro, I predict we'd trade above .20 cents on that alone....forget about everything else. But if we do get that kind of BP response to Lympro in January, that will put a spark in shareholder enthusiasm and they'll start getting excited about Eltoprazine and ESS too! But it's LymPro first (and the promise of revenue it brings) and then everything else will fall in place nicely.
Without LymPro revenue, we only fund everything else with dilution. That would be another wet blanket.
I can wait to up list until February. Personally, I hope we don't partner yet. I am hoping AMBS starts signing up pharmas doing AD trials. If we start seeing commitments from pharmas to use Lympro in January, the stock price will shoot up without the up front cash of a partner!! And then in 6 to 12 months, a partner will pay us 100x to partner with us on LymPro. (You got the quote right.)
I will be happy if the "launch" means: 1) We get the most recent Lympro data, and 2) We get 2 or 3 pharmas committed to Lympro by the end of January. If that happens, everything else will take care of itself....trust me.
All the surges we've had in stock price have always been associated with enthusiasm over Lympro. Jason Napodana took a dump on LymPro with his 1 million revenue estimate for 2015. That put a wet blanket over the stock price. If during the "launch" Gerald dispels that estimate and gives us better guidance aligned with his previous "significant portion of the 150 million RUO market in 2015," the stock price will start moving up.
If by the end of January we have 3 pharma commitments to use LymPro, I predict we'd trade above .20 cents on that alone....forget about everything else. But if we do get that kind of BP response to Lympro in January, that will put a spark in shareholder enthusiasm and they'll start getting excited about Eltoprazine and ESS too! But it's LymPro first (and the promise of revenue it brings) and then everything else will fall in place nicely.
Without LymPro revenue, we only fund everything else with dilution. That would be another wet blanket.
(0)
(0)